Olmesartan Clearance
Olmesartan is eliminated through dual pathways: approximately 35-50% is excreted unchanged in the urine via glomerular filtration and tubular secretion, while the remaining 50-65% is eliminated in feces via biliary excretion. 1
Elimination Pathways
Renal Clearance
- Renal clearance: 0.6 L/h (approximately 40% of systemically available olmesartan) 1, 2
- Excreted unchanged in urine without further metabolism
- Accounts for 35-50% of absorbed dose 1
- Occurs via glomerular filtration and tubular secretion
Hepatobiliary Clearance
- Total plasma clearance: 1.3 L/h 1
- Remainder (50-65%) eliminated in feces via bile 1
- Provides compensatory pathway when renal function is impaired 3, 4
Metabolism
Olmesartan undergoes virtually no metabolism after conversion from its prodrug form. 1
- Olmesartan medoxomil (prodrug) is rapidly and completely converted to olmesartan by ester hydrolysis during GI absorption
- Once formed, olmesartan is not metabolized by cytochrome P450 enzymes 3, 4
- No active or inactive metabolites are produced
- This lack of hepatic metabolism minimizes drug-drug interaction potential 2, 3
Pharmacokinetic Parameters
- Terminal elimination half-life: Approximately 13 hours (biphasic elimination) 1
- Volume of distribution: 17 L (limited extravascular tissue distribution) 1
- Protein binding: 99% (highly bound to plasma proteins) 1
- Steady-state: Achieved within 3-5 days with once-daily dosing 1
Clinical Implications
Renal Impairment
In severe renal insufficiency (creatinine clearance <20 mL/min), AUC increases approximately 3-fold due to reduced renal clearance 1. However, the dual elimination pathway allows hepatobiliary compensation, providing some safety margin.
Hepatic Impairment
Moderate hepatic impairment increases AUC by approximately 60% 1. The renal elimination pathway can partially compensate for reduced biliary excretion 3, 4.
Key Advantage
The dual elimination mechanism (renal + biliary) allows one pathway to compensate when the other is compromised, making olmesartan relatively safer in patients with single-organ dysfunction compared to drugs relying on a single elimination route 3, 4.